NYSE:CBM Cambrex (CBM) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free CBM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$59.99▼$59.9950-Day Range$59.99▼$59.9952-Week Range$33.80▼$60.29VolumeN/AAverage Volume218,726 shsMarket Capitalization$2.02 billionP/E Ratio21.66Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Cambrex alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Cambrex Stock (NYSE:CBM)Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. CBM Stock News HeadlinesMarch 27, 2024 | tmcnet.comOne Equity Partners Invests in Italian Agricultural Tractor Attachment Manufacturer CBMMarch 19, 2024 | morningstar.comChina CBM Group Co Ltd 08270April 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.November 2, 2023 | finance.yahoo.comCambrex Announces Sale of Drug Product Business UnitOctober 29, 2023 | investing.comCBM_old Historical DataOctober 24, 2023 | finance.yahoo.comSnapdragon Chemistry, a Cambrex Company, Recognized with CPhI Pharma Award for API DevelopmentOctober 18, 2023 | stockhouse.comSK pharmteco to showcase its extensive APIs and CGT capabilities in CPHI 2023September 21, 2023 | businesswire.comSK pharmteco to Expand Capabilities with Acquisition of Controlling Interest in Center for Breakthrough MedicinesApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.September 7, 2023 | finance.yahoo.comCleantech Building Materials: Result of General MeetingAugust 29, 2023 | markets.businessinsider.comDIVERGENT Energy Services Announces the Release of 2023 Second Quarter ResultsAugust 14, 2023 | finance.yahoo.comCleantech Building Materials: Notice of General MeetingMay 31, 2023 | markets.businessinsider.comCambrex Celebrates Grand Opening of New Q1 Scientific Facility in Belgium and Secures First Stability Storage Commercial AgreementMay 30, 2023 | juniorminingnetwork.comCollective Mining Drills 162.20 Metres at 3.90 g/t Gold Equivalent From Surface at the...January 18, 2023 | prnewswire.comCambrex fait l'acquisition de Snapdragon Chemistry, un leader dans les services de développement d'IPA à flux continuDecember 24, 2022 | msn.comRepair works at LRT, MRT, Monorail stations to be completed by FebruaryOctober 14, 2022 | businesswire.comVitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2028 - ResearchAndMarkets.com - Business WireOctober 9, 2022 | benzinga.comWith 5.0% CAGR, Small Molecule API Market Size Worth US$ 300.2 Billion by 2030 | Research for Developing - BenzingaOctober 5, 2022 | markets.businessinsider.comCambrex Announces Stability Storage Expansions in Ireland and BelgiumOctober 4, 2022 | prnewswire.comCambrex Announces Stability Storage Expansions in Ireland and Belgium - PR NewswireSeptember 28, 2022 | streetinsider.comMedicx Health Appoints Theresa Greco as President and Stacey Levas as Senior Vice President of Marketing - StreetInsider.comSeptember 27, 2022 | prnewswire.comInvestigational New Drug CDMO Market worth $7.47 billion by 2030 - Exclusive Report by InsightAce Analytic - PR NewswireSeptember 20, 2022 | finance.yahoo.comBlockchain Moon Acquisition Corp. appoints John P. Hopkins and Carl J. Johnson as new Independent Directors - Yahoo FinanceSeptember 19, 2022 | msn.comONGC wants government to scrap windfall tax on domestically produced crude oilSeptember 19, 2022 | msn.comONGC wants govt to scrap windfall tax, USD 10 gas priceSeptember 16, 2022 | businesswire.comKimball Electronics, Inc. Announces Appointment of Additional Director - Business WireSeptember 2, 2022 | news.yahoo.comCambrex finishes first phase of expansion - Yahoo NewsSee More Headlines Receive CBM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cambrex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/02/2018Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical Preparations Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:CBM CUSIP13201110 CIK820081 Webwww.cambrex.com Phone201-804-3000FaxN/AEmployees1,732Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$2.77 Trailing P/E Ratio21.66 Forward P/E RatioN/A P/E GrowthN/ANet Income$92.41 million Net Margins5.96% Pretax MarginN/A Return on Equity5.38% Return on Assets2.50% Debt Debt-to-Equity Ratio0.76 Current Ratio2.37 Quick Ratio1.70 Sales & Book Value Annual Sales$532.09 million Price / Sales3.80 Cash Flow$3.91 per share Price / Cash Flow15.36 Book Value$19.48 per share Price / Book3.08Miscellaneous Outstanding Shares33,720,000Free FloatN/AMarket Cap$2.02 billion OptionableOptionable Beta2.14 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Steven M. Klosk (Age 62)Pres, CEO & Director Mr. Gregory P. Sargen (Age 53)Exec. VP of Corp. Devel. & Strategy and CFO Mr. Shawn P. Cavanagh (Age 53)Exec. VP & COO Ms. Samantha M. Hanley (Age 41)VP, Gen. Counsel & Corp. Sec. Mr. James G. Farrell (Age 52)VP & Corp. Controller Key CompetitorsAvidity BiosciencesNASDAQ:RNAAmphastar PharmaceuticalsNASDAQ:AMPHKeros TherapeuticsNASDAQ:KROSPTC TherapeuticsNASDAQ:PTCTMaravai LifeSciencesNASDAQ:MRVIView All Competitors CBM Stock Analysis - Frequently Asked Questions How were Cambrex's earnings last quarter? Cambrex Co. (NYSE:CBM) announced its quarterly earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.05. The biotechnology company earned $152.05 million during the quarter, compared to analysts' expectations of $132.78 million. Cambrex had a trailing twelve-month return on equity of 5.38% and a net margin of 5.96%. Cambrex's revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.76 EPS. What other stocks do shareholders of Cambrex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Illumina (ILMN), AbbVie (ABBV), NVIDIA (NVDA), CVS Health (CVS), Gilead Sciences (GILD), Intel (INTC), Walt Disney (DIS), Juno Therapeutics (JUNO) and Under Armour (UAA). This page (NYSE:CBM) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cambrex Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
